Treatment of Adolescent Depression and Anxiety

Introduction to Treatment Options

• Cognitive Behavioral Therapy (CBT) and Interpersonal Psychotherapy (IPT-A) are recommended as first-line treatments for adolescents with depression and anxiety disorders, with medication added for moderate to severe cases or when psychotherapy alone is insufficient, as recommended by the American Academy of Pediatrics and the American Academy of Child and Adolescent Psychiatry 1, 2
• Combined therapy approaches, such as CBT with fluoxetine, are more effective than either treatment alone for moderate to severe depression, highlighting the importance of combined therapy approaches 1
• CBT and IPT-A have demonstrated effectiveness for depression, showing large improvements in symptoms, and are considered probably efficacious treatments for adolescent depression 1

Medication Options

• Fluoxetine is the most evidence-supported medication for depression in adolescents, with the American Academy of Pediatrics recommending its use as a first-line treatment 1
• Selective serotonin reuptake inhibitors (SSRIs) are first-line pharmacotherapy for anxiety disorders in adolescents, according to the American Academy of Child and Adolescent Psychiatry 2
• The following medications have recommended starting and target doses:

3, 4, 5

• SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs) are effective first-line treatments for depression and anxiety disorders, with SSRIs generally preferred as initial therapy due to better tolerability, while SNRIs may offer advantages in patients with comorbid chronic pain or treatment-resistant depression 3, 6

Treatment Considerations

• Anxiety disorders are highly comorbid with other psychiatric disorders, particularly depression, but also ADHD, learning disorders, and behavior disorders, as highlighted by the American Academy of Child and Adolescent Psychiatry 2
• Family involvement, including parent/parenting factors and family environment, plays a crucial role in treatment outcomes, as noted by the American Academy of Child and Adolescent Psychiatry and the Annual Review of Clinical Psychology 2, 7
• Developmental considerations are important in treatment, as different anxiety disorders often onset during specific developmental phases, according to the American Academy of Child and Adolescent Psychiatry 2

Treatment Approaches for Specific Conditions

• For mild depression or anxiety, begin with CBT or IPT-A as first-line treatment, as recommended by the American Academy of Pediatrics and the American Academy of Child and Adolescent Psychiatry 1, 2
• For moderate to severe depression or anxiety, consider a combination of psychotherapy (CBT or IPT-A) plus medication, with fluoxetine being the most evidence-supported medication for depression, according to the American Academy of Pediatrics 1
• Specialized psychosocial treatments like MBCT-C (Mindfulness-Based Cognitive Therapy for Children) show promise for youth with bipolar disorder and anxiety, as noted by the Annual Review of Clinical Psychology 7
• Second-generation antipsychotics have the strongest evidence for augmentation of SNRIs in anxiety disorders, with quetiapine showing particular benefit for generalized anxiety symptoms, according to the American Academy of Child and Adolescent Psychiatry 8

Alternative and Complementary Therapies

• Structured physical activity and exercise show benefit for anxiety reduction, according to the American College of Sports Medicine 9
• Several over-the-counter supplements, including lavender, passionflower, and melatonin, have shown effectiveness for anxiety reduction, with the strongest evidence for safety and efficacy, according to the Mayo Clinic Proceedings 10
• Omega-3 fatty acids have the strongest evidence for treating anxiety disorders, with recommended dosages of 1-2g daily of EPA from either pure EPA or an EPA/DHA combination with a ratio greater than 2:1, as recommended by the American Psychiatric Association 11

Treatment Duration and Discontinuation

• Continue treatment for at least 4-9 months after satisfactory response, with initial follow-up within 1-2 weeks of starting medication and regular monitoring during dose titration 3
• Effective treatment should be continued for approximately 1 year following symptom remission, although the exact duration may vary depending on individual patient needs 2
• Selective serotonin-norepinephrine reuptake inhibitors (SNRIs) should be discontinued through a slow, gradual tapering schedule over several weeks to months, with dose reductions of approximately 25% every 1-2 weeks to minimize discontinuation side effects, as recommended by the American Academy of Child and Adolescent Psychiatry 2